Literature DB >> 9671378

Differential expression of inducible nitric oxide synthase messenger RNA along the longitudinal and crypt-villus axes of the intestine in endotoxemic rats.

M J Morin1, N Unno, R A Hodin, M P Fink.   

Abstract

OBJECTIVES: To characterize the mechanisms leading to excessive production of nitric oxide within the gut as a consequence of endotoxemia. We sought to: a) determine the time course of inducible nitric oxide synthase (iNOS) messenger RNA (mRNA) expression in the intestine after challenging rats with lipopolysaccharide (LPS); and b) investigate whether there is differential expression of iNOS in enterocytes along the longitudinal or crypt-villus axes of the intestine in rats after LPS administration.
DESIGN: Prospective, randomized, unblinded study.
SETTING: Research laboratories at a large university-affiliated medical center.
SUBJECTS: Male Sprague-Dawley rats.
INTERVENTIONS: At T = 0 hr, rats were injected with O111:B4 Escherichia coli LPS (5 mg/kg) or a similar volume of the saline vehicle. At various time points thereafter, samples of duodenum, jejunum, ileum, colon, and liver were harvested for subsequent extraction of RNA. In some cases, populations of enterocytes enriched in either crypt or villus cells were harvested from the ileum. In some studies, rats were injected with cycloheximide (25 mg i.p.) 15 mins before being challenged with LPS or dexamethasone (2 mg i.p.) 30 mins before being injected with LPS.
MEASUREMENTS AND MAIN RESULTS: iNOS mRNA was undetectable in ileal tissue from rats under basal conditions, but was evident by T = 1 hr and was maximal at T = 2 hrs after injection of LPS. Thereafter, ileal iNOS mRNA concentrations decreased and were undetectable again at T = 24 hrs. At T = 2 hrs after LPS injection, there was marked expression of iNOS mRNA in the ileum, whereas much lower concentrations of iNOS mRNA were detected in the jejunum and colon, and no iNOS mRNA was detected in the duodenum. At T = 3 hrs after LPS injection, expression of iNOS mRNA was up-regulated in both villus and crypt cells, although LPS-induced iNOS mRNA was more prominent in the former than the latter cell type. Pretreatment of rats with dexamethasone virtually abrogated the expression of iNOS mRNA in ileal samples obtained 3 hrs after the injection of LPS. Prior treatment of rats with the protein synthesis inhibitor, cycloheximide, also blunted LPS-induced iNOS mRNA expression.
CONCLUSIONS: LPS-induced iNOS expression is differentially regulated along both the longitudinal and crypt villus axes of the intestinal mucosa, being most prominent in the villus cells of the ileum. LPS-induced iNOS expression is blunted by pretreating rats with dexamethasone or cycloheximide. The latter finding suggests that LPS-induced expression of iNOS mRNA in the gut requires new protein synthesis. Differential regulation of nitric oxide production along the longitudinal and crypt-villus axes of the gut may be a determinant of the pattern of sepsis-induced intestinal damage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671378     DOI: 10.1097/00003246-199807000-00031

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  22 in total

1.  In vivo measurement of nitric oxide production in porcine gut, liver and muscle during hyperdynamic endotoxaemia.

Authors:  Maaike J Bruins; Wouter H Lamers; Alfred J Meijer; Peter B Soeters; Nicolaas E P Deutz
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Sublingual microcirculation in pulmonary arterial hypertension.

Authors:  Luma Dababneh; Frank Cikach; Laith Alkukhun; Raed A Dweik; Adriano R Tonelli
Journal:  Ann Am Thorac Soc       Date:  2014-05

3.  Acquired interferon gamma responsiveness during Caco-2 cell differentiation: effects on iNOS gene expression.

Authors:  A M Chavez; M J Morin; N Unno; M P Fink; R A Hodin
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

4.  Inducible nitric oxide synthase inhibition improves intestinal microcirculatory oxygenation and CO2 balance during endotoxemia in pigs.

Authors:  Martin Siegemund; Jasper van Bommel; Lothar A Schwarte; Wolfgang Studer; Thierry Girard; Stephan Marsch; Peter Radermacher; Can Ince
Journal:  Intensive Care Med       Date:  2005-06-15       Impact factor: 17.440

5.  Lipopolysaccharide-induced bacterial translocation is intestine site-specific and associates with intestinal mucosal inflammation.

Authors:  Chao Yue; Bingqiang Ma; Yunzhao Zhao; Qiurong Li; Jieshou Li
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

6.  Temporal expression of tumor necrosis factor-alpha and nitric oxide synthase 2 in rat small intestine after endotoxin.

Authors:  R Arya; V B Grossie; N W Weisbrodt; M Lai; D Mailman; F Moody
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

7.  Regulation of induction of nitric oxide synthase and the inhibitory actions of dexamethasone in the human intestinal epithelial cell line, Caco-2: influence of cell differentiation.

Authors:  M Cavicchi; B J Whittle
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 8.  iNOS expression in oral and gastrointestinal tract mucosa.

Authors:  Nurullah Keklikoglu; Meltem Koray; Humeyra Kocaelli; Sevtap Akinci
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

9.  Extracellular activation of arginase-1 decreases enterocyte inducible nitric oxide synthase activity during systemic inflammation.

Authors:  Keita Miki; Abhai Kumar; Runkuan Yang; Meaghan E Killeen; Russell L Delude
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-08-27       Impact factor: 4.052

Review 10.  Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials.

Authors:  Stephen Trzeciak; Ismail Cinel; R Phillip Dellinger; Nathan I Shapiro; Ryan C Arnold; Joseph E Parrillo; Steven M Hollenberg
Journal:  Acad Emerg Med       Date:  2008-05       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.